echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Nat Med: Efficacy analysis of second dose of BNT162b2 for COVID-19 hospitalizations and deaths in adults over 60 years of age

    Nat Med: Efficacy analysis of second dose of BNT162b2 for COVID-19 hospitalizations and deaths in adults over 60 years of age

    • Last Update: 2022-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The B.
    1.
    1.
    529 (Omicron) variant of SARS-CoV-2 was first identified in South Africa in early November 2021, leading
    to an unprecedented global resurgence and widespread prevalence of coronavirus disease 2019 (
    COVID-19 ) spread
    .
    Israeli authorities have approved the initiation of a fourth dose of the COVID-19 vaccine (ie, the second booster dose) for individuals aged 60 years and older who received the first booster dose four months or more after the last dose

    .
    Therefore, it is imperative to collect and collate evidence on the effectiveness of the second booster in reducing hospitalizations and mortality due to COVID-19

    .

    COVID-19

    Recently, a research article was published in the top medical journal Nature Medicine.
    This retrospective cohort study included all members of the Clalit Medical Service, who were between the ages of 60 and 100 and who were eligible by January 3, 2022.
    Received a second booster shot of the vaccine

    .

    The researchers compared hospitalizations and mortality from COVID-19 in participants who received a second booster immunization
    with those who received only one booster immunization .
    In addition, we used Cox proportional hazards regression models with time-dependent covariates to estimate the association between a second booster immunization and hospitalizations and deaths from COVID-19, adjusting for demographic factors and comorbidities

    .

    immunity

    A total of 563,465 participants in the study met study eligibility and criteria
    .
    Of these, 328,597 (58%) received a second booster vaccination during the 40-day study period

    .
    Hospitalization for COVID-19 occurred in 270 who received the second booster vaccine and 550 who received only one booster vaccine (adjusted hazard ratio, 0.
    36; 95% confidence interval (CI), 0.
    31 to 0.
    43)

    .
    Death from COVID-19 occurred in 92 participants who received the second booster vaccine and 232 who received only one booster vaccine (adjusted hazard ratio, 0.
    22; 95% CI, 0.
    17 to 0.
    28)

    .

    The study showed that among Israeli adults aged 60 years and older, hospitalizations and deaths due to Covid-19 were significantly reduced as a result of a second booster vaccine
    .

    Among Israeli adults aged 60 and older, hospitalizations and deaths due to Covid-19 have fallen sharply as a result of a second booster vaccine
    .

    Original source:

    Original source:

    Ronen Arbel, et al.
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years .
    Nature Medicine.
    2022.
    https://
    -0_reference.
    pdf

    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.